AlkermesALKS +4.96%70 OCF Margin % is -42.18% as of Mar. 2026. GuruFocus rates ALKS with a GF Score™ of 70/100 and a GF Value™ of $31.33 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 959 Drug Manufacturers companies, Alkermes ranks better than 69.55% on this metric.
The historical rank and industry rank for Alkermes's OCF Margin % or its related term are showing as below:
ALKS'
s OCF Margin % Range Over the Past 10 Years
Min: -8.56 Med: 8.33 Max: 35.28
Current: 16.4
During the past 13 years, the highest OCF Margin % of Alkermes was 35.28%. The lowest was -8.56%. And the median was 8.33%.
ALKS's OCF Margin % is ranked better than 69.55% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs ALKS: 16.40
Alkermes OCF Margin % Related Terms
Alkermes OCF Margin % Historical Data
* Premium members only.
The historical data trend for Alkermes's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkermes OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkermes's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Alkermes's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes (ALKS) has a OCF Margin % of -42.18% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alkermes and its competitors. According to the industry distribution chart, Alkermes ranks #292 out of 959 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Alkermes' OCF Margin % too high?
Alkermes' current OCF Margin % is -42.18%. Based on the distribution chart, Alkermes ranks #292 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkermes has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' OCF Margin % compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Alkermes ranks #292 out of 959 companies for OCF Margin %. This puts Alkermes in the upper half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alkermes and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkermes's current OCF Margin % is -42.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.33, compared to a current price of $50.45 — trading 61% above its estimated fair value. The current OCF Margin % is -42.18%. Alkermes' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Alkermes (ALKS), the current OCF Margin % is -42.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkermes (ALKS) Overvalued in 2026?
Based on GuruFocus' analysis, Alkermes stock appears to be overvalued.
The current stock price of $50.45 is trading 61% above its estimated GF Value™ of $31.33.
GuruFocus considers Alkermes to be Significantly Overvalued.
Key valuation signals for ALKS:
OCF Margin %: -42.18%
GF Value™: $31.33 vs. price of $50.45 (61% above fair value)
No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
70GF Score
Get the complete analysis for ALKS
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALKS has been successfully added to your 
